MAY 21, 2015
Academy Urges FDA to Extend Beyond-Use Dates for Repackaged Biologics
This week, the Academy submitted comments to the U.S. Food and Drug Administration to oppose the agency’s proposed guidance on repackaged biologics, including bevacizumab.